Novartis AG

The combined Teva–Allergan generics entity should have approximately 320 Abbreviated New Drug Applications (or ANDAs), including 110 first-to-file ANDAs (or FTF) in the US.

Spark Therapeutics generated revenues of $25.18 million in the second quarter of 2018 compared to $1.48 million in Q2 2017.

Merck provided revenue guidance of $39.7 billion–$40.2 billion in 2016. It expects negative foreign exchange fluctuations to reduce its fiscal 2016 revenue.

On July 22, 2015, Biogen (BIIB) released data from a Phase 1b study, also called the PRIME Study, that looked at the effectiveness of its investigational Alzheimer’s drug, BIIB037.

For 2016, Merck & Co. (MRK) reported revenue close to $39.8 billion, a year-over-year (or YoY) rise of ~1%. New product launches have played major roles in boosting Merck’s 2016 revenue.

Dermatology pricing trends Valeant Pharmaceuticals’ (VRX) dermatology business witnessed intense pricing pressure in 2016, due to a change in the company’s distribution model in 4Q15. While Valeant previously marketed its dermatology drugs through specialty pharmacies, the company now distributes its products through Walgreens. To learn about the company’s current distribution model, please refer to How Valeant Plans […]

In 2016, Regeneron expects to face increased competition from Roche Holding’s Lucentis (Ranibizumab) and Avastin (Bevacizumab) for Eylea.

In 2Q17, Inlyta generated revenues of ~$88 million, which represents an ~19% decline on a YoY basis and ~4% growth on a quarter-over-quarter basis.

Teva Pharmaceutical (TEVA) expects its 2017 non-generally accepted accounting principles (non-GAAP) earnings per share (or EPS) to fall in the range of $4.9–$5.3.

Regeneron Pharmaceuticals (REGN) depends heavily upon its key drug, Eylea, which recorded global sales of $4.1 billion during fiscal 2015.

In 2016, Merck’s (MRK) Emend reported revenues of around $549 million, which reflected 3% year-over-year growth.

Since its launch in February 2015, Pfizer’s Ibrance has quickly captured the advanced breast cancer market and has reached more than 40,000 patients.

Today, Teva Pharmaceutical Industries (TEVA) announced that its Granix (tbo-filgrastim) injection has received FDA approval for a new presentation and indication.

In January 2018, the FDA granted a BTD to Novartis’s (NVS) Promacta for use along with standard immunosuppressive therapy.

Approved by the FDA on September 14, Teva’s Ajovy has multiple competitors set to enter the market.

To ensure long-term relevance as well as quick adaptability to changing market needs, Novartis (NVS) is focusing on five major initiatives in 2017.

Novartis (NVS) and Amgen (AMGN) recently announced that the CGRP inhibitor therapy, AMG 334, reported positive results in a Phase 2 clinical trial as a therapy for preventing chronic migraine.

Teva Pharmaceutical Industries accounts for 18% of the US generic drug market. This share is significantly higher than those of Mylan, Novartis, and Pfizer.

Merial, Sanofi’s (SNY) Animal Health segment, reported total revenues of 725 million euros (about $818.6 million), which is a 9.1% increase over 2Q15.

Rx for Growth? The trillion-dollar pharmaceutical industry has historically been dominated by a few major companies that create and supply the most important branded prescriptions on the market. Recent trends, however, point to the growth of the newest pharma blockbusters: generics. Today, approximately 60% of Americans take prescription drugs;[1. “Trends in Prescription Drug Use Among […]

Approximately 85% of all lung cancers in the United States are non-small cell lung cancers, and 10% to 15% of these are EGFR mutation-positive.

Novartis’s Innovative Medicines segment, formerly referred to as the Pharmaceutical segment, consists of products for a variety of therapeutic areas.

In December 2017, Kite, a Gilead Sciences (GILD) company, presented long-term follow-up data from its pivotal ZUMA-1 trial of Yescarta.

In July 2017, the FDA accepted Bristol-Myers Squibb’s supplemental New Drug Application (or sNDA) for expanding the indication of Sprycel.

The overall contribution of the Innovative Medicines segment is ~67% of Novartis’s total revenues.

In 2Q17, Amgen’s (AMGN) Aranesp generated revenues of ~$535 million, which represented a 6% year-over-year rise.

In fiscal 1Q18, Teva (TEVA) reported sales of $645 million for its multiple sclerosis drug, Copaxone, a sequential decline of ~21%.

Yesterday, Teva Pharmaceutical Industries (TEVA) announced the exclusive FTF (first-to-file) launch of the generic Cialis1 tablets in the US.

In 2018, the global pharmaceutical industry stood at $1.2 trillion, and experts expect $1.5 trillion by 2023. Here’s everything investors need to know.

Zoetis said in a recent statement that “its unique characteristics have established the company as the world leader in animal health, growing revenue faster than the market for the last three years.”

AbbVie (ABBV) has projected Imbruvica’s annual revenues to be $5 billion by 2020. That would be driven by a rapid uptake in the first line chronic lymphocytic leukemia (or CLL) segment.

Ignyta (RXDX) has completed enrollment for a Phase 1 clinical trial of RXDX-105, an orally bioavailable small molecule tyrosine kinase inhibitor.

Ignyta’s (RXDX) R&D (research and development) expenses increased from $16.6 million in 3Q16 to $21.7 million in 3Q17, a 30% rise.

In October 2017, Ignyta (RXDX) raised $150 million by issuing 10 million shares of its common stock.

According to the company’s fourth-quarter earnings conference call, Novartis expects to complete the spin-off of its Alcon business in the second quarter of 2019.

Since fiscal 2018, Novartis (NVS) has been focused on transforming itself into a new focused medicines company.

In the first quarter, Novartis’s (NVS) Cosentyx reported net sales of $791 million, a YoY (year-over-year) rise of 41% on a constant currency basis.

Wall Street analysts have projected Spark Therapeutics’ revenues to be $105.64 million, $169.22 million, and $263.76 million for fiscal 2019, fiscal 2020, and fiscal 2021, respectively.

GSK highlighted the prioritization of research and development programs, business development, and new product launches as its key growth drivers in 2018.

On September 14, Teva Pharmaceutical (TEVA) issued a press release announcing FDA approval of humanized monoclonal antibody and anti-calcitonin gene-related peptide (or CGRP) therapy.

On November 16, Merck’s stock price closed at $76.06, which represents ~1.63% growth from its close of $74.84 on November 15.

Jazz Pharmaceuticals’ Xyrem generated revenues of $357.3 million in the third quarter—compared to $303.9 million in the third quarter of 2017.

Merck & Co.’s (MRK) Januvia generated revenues of $927 million in the third quarter, reflecting an ~8% YoY (year-over-year) decline.

Alcon reported revenue of ~$1.82 billion in the second quarter, a 7% rise.

In June, PTC Therapeutics (PTCT) presented its updated interim clinical data from the Phase 1 FIREFISH trial.

Verzenio has demonstrated double-digit growth in new patient usage in patient segments targeted by the drug’s first two approved indications.

In 1Q18, Amgen’s (AMGN) Nplate revenue grew 16% YoY (year-over-year) to $179 million from $154 million, primarily driven by unit demand.

In 4Q17, Novartis’s (NVS) Galvus generated revenues of $327 million, which is ~10% growth on a year-over-year (or YoY) basis and 5% growth quarter-over-quarter.

In 4Q17, Novartis’s (NVS) Xolair generated revenues of $247 million, which reflected ~14% growth on a year-over-year (or YoY) basis and ~1% growth on a quarter-over-quarter basis.

In 4Q17, Novartis’s Immunology and Dermatology segment generated revenues of $1.2 billion, ~30% growth on a year-over-year (or YoY) basis and ~9% growth quarter-over-quarter.